Advertisement

New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease

  • Laura Best
  • Christine GhaderyEmail author
  • Nicola Pavese
  • Yen Foung Tai
  • Antonio P. Strafella
Neuroimaging (N. Pavese, Section Editor)
  • 92 Downloads
Part of the following topical collections:
  1. Topical Collection on Neuroimaging

Abstract

Purpose of Review

We will discuss the developments in TSPO PET imaging and the contribution this technique has had to understanding neuroinflammation in vivo, as well as the limitations inherent to the currently available radioligands and the potential future direction.

Recent Findings

Positron emission tomography (PET) imaging targeting the translocator protein 18 kDa (TSPO) has led to major advances in understanding the pathological role played by microglia activation and neuroinflammation in a diverse range of neurodegenerative conditions.

Summary

The first-generation radioligand 11[C](R)-PK11195 has been the most widely studied and has led to considerable advancements in defining the role of neuroinflammation in neuronal degeneration and dysfunction. However, limitations including low signal-to-noise ratio and high nonspecific binding have led to the development of new TSPO-specific radioligands in an attempt to improve the quality of TSPO imaging. Unfortunately, these new radioligands have not been without their own problems, and the expected improvement in image quality has not been achieved.

Keywords

Neuroinflammation Microglial activation TSPO PET Neurodegenerative diseases 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapère J-J, Lindemann P, et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27(8):402–9.PubMedGoogle Scholar
  2. 2.
    •• Dupont A-C, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Tronel C, Arlicot N. Translocator protein-18 kDa (TSPO) positron emission tomography (PET) imaging and its clinical impact in neurodegenerative diseases. Int J Mol Sci. 2017;18(4) The authors outline the in vivo exploration of neuroinflammation in neurodegenerative and neuropsychiatric conditions, including major advances and the clinical impact of TSPO impact to date. PubMedCentralGoogle Scholar
  3. 3.
    Le Fur G, Perrier ML, Vaucher N, Imbault F, Flamier A, Benavides J, et al. Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies. Life Sci. 1983;32(16):1839–47.PubMedGoogle Scholar
  4. 4.
    Chauveau F, Boutin H, Van Camp N, Dollé F, Tavitian B. Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging. 2008;35(12):2304–19.PubMedGoogle Scholar
  5. 5.
    Fujimura Y, Zoghbi SS, Simeon FG, Taku A, Pike VW, Innis RB, et al. Quantification of translocator protein (18 kDa) in the human brain with PET and a novel radioligand, 18F-PBR06. J Nucl Med. 2009;50(7):1047–53.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Fujimura Y, Ikoma Y, Yasuno F, Suhara T, Ota M, Matsumoto R, et al. Quantitative analyses of 18F-FEDAA1106 binding to peripheral benzodiazepine receptors in living human brain. J Nucl Med. 2006;47(1):43–50.PubMedGoogle Scholar
  7. 7.
    Wilson AA, Garcia A, Parkes J, McCormick P, Stephenson KA, Houle S, et al. Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. Nucl Med Biol. 2008;35(3):305–14.PubMedGoogle Scholar
  8. 8.
    Ikoma Y, Yasuno F, Ito H, Suhara T, Ota M, Toyama H, et al. Quantitative analysis for estimating binding potential of the peripheral benzodiazepine receptor with [ 11 C]DAA1106. J Cereb Blood Flow Metab. 2007;27(1):173–84.PubMedGoogle Scholar
  9. 9.
    Boutin H, Chauveau F, Thominiaux C, Grégoire M-C, James ML, Trebossen R, et al. 11C-DPA-713: a novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation. J Nucl Med. 2007;48(4):573–81.PubMedGoogle Scholar
  10. 10.
    Fookes CJR, Pham TQ, Mattner F, Greguric I, Loc’h C, Liu X, et al. Synthesis and biological evaluation of substituted [18F]imidazo[1,2-a] pyridines and [18F]pyrazolo[1,5-a] pyrimidines for the study of the peripheral benzodiazepine receptor using positron emission tomography. J Med Chem. 2008;51(13):3700–12.PubMedGoogle Scholar
  11. 11.
    Van Camp N, Boisgard R, Kuhnast B, Thézé B, Viel T, Grégoire M-C, et al. In vivo imaging of neuroinflammation: a comparative study between [(18)F]PBR111, [(11)C] CLINME and [(11)C]PK11195 in an acute rodent model. Eur J Nucl Med Mol Imaging. 2010;37(5):962–72.PubMedGoogle Scholar
  12. 12.
    Arlicot N, Vercouillie J, Ribeiro M-J, Tauber C, Venel Y, Baulieu J-L, et al. Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. Nucl Med Biol. 2012;39(4):570–8.PubMedGoogle Scholar
  13. 13.
    Fujita M, Imaizumi M, Zoghbi SS, Fujimura Y, Farris AG, Suhara T, et al. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. NeuroImage. 2008;40(1):43–52.PubMedGoogle Scholar
  14. 14.
    Endres CJ, Pomper MG, James M, Uzuner O, Hammoud DA, Watkins CC, et al. Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. J Nucl Med. 2009;50(8):1276–82.PubMedPubMedCentralGoogle Scholar
  15. 15.
    • Vivash L, O’Brien TJ. Imaging microglial activation with TSPO PET: lighting up neurologic diseases? J Nucl Med. 2016;57(2):165–8 This review summarises the recent developments in TSPO imaging, including the current limitations and possibilities for future direction in this field. PubMedGoogle Scholar
  16. 16.
    Kreisl WC, Fujita M, Fujimura Y, Kimura N, Jenko KJ, Kannan P, et al. Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker. NeuroImage. 2010;49(4):2924–32.PubMedGoogle Scholar
  17. 17.
    Owen DRJ, Gunn RN, Rabiner EA, Bennacef I, Fujita M, Kreisl WC, et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med. 2011;52(1):24–32.PubMedGoogle Scholar
  18. 18.
    Owen DRJ, Matthews PM. Imaging brain microglial activation using positron emission tomography and translocator protein-specific radioligands. Int Rev Neurobiol. 2011;101:19–39.PubMedGoogle Scholar
  19. 19.
    Owen DR, Howell OW, Tang S-P, Wells LA, Bennacef I, Bergstrom M, et al. Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab. 2010;30(9):1608–18.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32(1):1–5.PubMedGoogle Scholar
  21. 21.
    Guo Q, Owen DR, Rabiner EA, Turkheimer FE, Gunn RN. Identifying improved TSPO PET imaging probes through biomathematics: the impact of multiple TSPO binding sites in vivo. NeuroImage. 2012;60(2):902–10.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358(9280):461–7.PubMedGoogle Scholar
  23. 23.
    Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology. 2009;72(1):56–62.PubMedPubMedCentralGoogle Scholar
  24. 24.
    • Parbo P, Ismail R, Hansen KV, Amidi A, Mårup FH, Gottrup H, et al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer’s disease. Brain J Neurol. 2017;140(7):2002–11 This study found a positive correlation between amyloid load and PK binding potentials, revealing increased neuroinflammation in the majority of amyloid-positive cases of MCI. Google Scholar
  25. 25.
    Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, et al. Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol. 2009;66(1):60–7.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Schuitemaker A, Kropholler MA, Boellaard R, van der Flier WM, Kloet RW, van der Doef TF, et al. Microglial activation in Alzheimer’s disease: an (R)-[11C]PK11195 positron emission tomography study. Neurobiol Aging. 2013;34(1):128–36.PubMedGoogle Scholar
  27. 27.
    Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, et al. Microglia, amyloid, and cognition in Alzheimer’s disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 2008;32(3):412–9.Google Scholar
  28. 28.
    Yokokura M, Mori N, Yagi S, Yoshikawa E, Kikuchi M, Yoshihara Y, et al. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2011;38(2):343–51.PubMedGoogle Scholar
  29. 29.
    Fan Z, Aman Y, Ahmed I, Chetelat G, Landeau B, Ray Chaudhuri K, et al. Influence of microglial activation on neuronal function in Alzheimer’s and Parkinson’s disease dementia. Alzheimers Dement. 2015;11(6):608–621.e7.PubMedGoogle Scholar
  30. 30.
    Cagnin A, Rossor M, Sampson EL, Mackinnon T, Banati RB. In vivo detection of microglial activation in frontotemporal dementia. Ann Neurol. 2004;56(6):894–7.PubMedGoogle Scholar
  31. 31.
    Yasuno F, Ota M, Kosaka J, Ito H, Higuchi M, Doronbekov TK, et al. Increased binding of peripheral benzodiazepine receptor in Alzheimer’s disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry. 2008;64(10):835–41.PubMedGoogle Scholar
  32. 32.
    Yasuno F, Kosaka J, Ota M, Higuchi M, Ito H, Fujimura Y, et al. Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [11C]DAA1106. Psychiatry Res. 2012;203(1):67–74.PubMedGoogle Scholar
  33. 33.
    Kreisl WC, Lyoo CH, McGwier M, Snow J, Jenko KJ, Kimura N, et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease. Brain J Neurol. 2013;136(Pt 7):2228–38.Google Scholar
  34. 34.
    Varrone A, Oikonen V, Forsberg A, Joutsa J, Takano A, Solin O, et al. Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F] FEMPA in Alzheimer’s disease patients and control subjects. Eur J Nucl Med Mol Imaging. 2015;42(3):438–46.PubMedGoogle Scholar
  35. 35.
    Lyoo CH, Ikawa M, Liow J-S, Zoghbi SS, Morse CL, Pike VW, et al. Cerebellum can serve as a pseudo-reference region in Alzheimer disease to detect neuroinflammation measured with PET radioligand binding to translocator protein. J Nucl Med. 2015;56(5):701–6.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Suridjan I, Rusjan PM, Kenk M, Verhoeff NPLG, Voineskos AN, Rotenberg D, et al. Quantitative imaging of neuroinflammation in human white matter: a positron emission tomography study with translocator protein 18 kDa radioligand, [18F]-FEPPA. Synapse. 2014;68(11):536–47.PubMedGoogle Scholar
  37. 37.
    Golla SSV, Boellaard R, Oikonen V, Hoffmann A, van Berckel BNM, Windhorst AD, et al. Quantification of [18F]DPA-714 binding in the human brain: initial studies in healthy controls and Alzheimer’s disease patients. J Cereb Blood Flow Metab. 2015;35(5):766–72.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Gulyás B, Vas A, Tóth M, Takano A, Varrone A, Cselényi Z, et al. Age and disease related changes in the translocator protein (TSPO) system in the human brain: positron emission tomography measurements with [11C]vinpocetine. NeuroImage. 2011;56(3):1111–21.PubMedGoogle Scholar
  39. 39.
    Varrone A, Mattsson P, Forsberg A, Takano A, Nag S, Gulyás B, et al. In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer’s disease patients. Eur J Nucl Med Mol Imaging. 2013;40(6):921–31.PubMedGoogle Scholar
  40. 40.
    • Hamelin L, Lagarde J, Dorothée G, Leroy C, Labit M, Comley RA, et al. Early and protective microglial activation in Alzheimer’s disease: a prospective study using 18F-DPA-714 PET imaging. Brain J Neurol. 2016;139(Pt 4):1252–64 This study compared AD patients with different rates of progression and found that TSPO binding was higher in patients with slower clinical progression, suggesting that neuroinflammation may play a protective role in the early stages. Google Scholar
  41. 41.
    Doble A, Malgouris C, Daniel M, Daniel N, Imbault F, Basbaum A, et al. Labelling of peripheral-type benzodiazepine binding sites in human brain with [3H] PK 11195: anatomical and subcellular distribution. Brain Res Bull. 1987;18(1):49–61.PubMedGoogle Scholar
  42. 42.
    Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Golla SSV, Boellaard R, Oikonen V, Hoffmann A, van Berckel BNM, Windhorst AD, et al. Parametric binding images of the TSPO ligand 18F-DPA-714. J Nucl Med. 2016;57(10):1543–7.PubMedGoogle Scholar
  44. 44.
    Fan Z, Okello AA, Brooks DJ, Edison P. Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer’s disease. Brain J Neurol. 2015;138(Pt 12):3685–98.Google Scholar
  45. 45.
    Kreisl WC, Lyoo CH, Liow J-S, Wei M, Snow J, Page E, et al. (11)C-PBR28 binding to translocator protein increases with progression of Alzheimer’s disease. Neurobiol Aging. 2016;44:53–61.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, Hammers A, et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med. 2007;48(1):158–67.PubMedGoogle Scholar
  47. 47.
    McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988;38(8):1285–91.Google Scholar
  48. 48.
    Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol. 2003;106(6):518–26.PubMedGoogle Scholar
  49. 49.
    Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann Neurol. 2005;57(2):168–75.PubMedGoogle Scholar
  50. 50.
    Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. 2006;21(2):404–12.PubMedGoogle Scholar
  51. 51.
    Bartels AL, Willemsen ATM, Doorduin J, de Vries EFJ, Dierckx RA, Leenders KL. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson’s disease? Parkinsonism Relat Disord. 2010;16(1):57–9.PubMedGoogle Scholar
  52. 52.
    Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Ray Chaudhuri K, et al. Microglia, amyloid, and glucose metabolism in Parkinson’s disease with and without dementia. Neuropsychopharmacology. 2013;38(6):938–49.PubMedPubMedCentralGoogle Scholar
  53. 53.
    • Terada T, Yokokura M, Yoshikawa E, Futatsubashi M, Kono S, Konishi T, et al. Extrastriatal spreading of microglial activation in Parkinson’s disease: a positron emission tomography study. Ann Nucl Med. 2016;30(8):579–87 Using the [ 11 C]DPA713 ligand, the role of microglial activation in the early stages of PD was analysed and the authors concluded that extrastriatal spreading of neuroinflammation occurs early in the pathophysiological process. PubMedGoogle Scholar
  54. 54.
    Koshimori Y, Ko J-H, Mizrahi R, Rusjan P, Mabrouk R, Jacobs MF, et al. Imaging striatal microglial activation in patients with Parkinson’s disease. PLoS One. 2015;10(9):e0138721.PubMedPubMedCentralGoogle Scholar
  55. 55.
    •• Ghadery C, Koshimori Y, Coakeley S, Harris M, Rusjan P, Kim J, et al. Microglial activation in Parkinson’s disease using [18F]-FEPPA. J Neuroinflammation. 2017 [cited 2018 Dec 4];14(1). Available from: http://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0778-1. This study investigated patients of HAB for the rs6791 polymorphism with MAB patients to assess regional differences in [ 18 F-FEPPA binding in PD patients and HCs. The results demonstrated a significant main effect of genotype on radioligand binding in all brain regions, but no effect of disease or disease and genotype interaction in any brain region.
  56. 56.
    Rusjan PM, Wilson AA, Bloomfield PM, Vitcu I, Meyer JH, Houle S, et al. Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography. J Cereb Blood Flow Metab. 2011;31(8):1807–16.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Iranzo A, Fernández-Arcos A, Tolosa E, Serradell M, Molinuevo JL, Valldeoriola F, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One. 2014;9(2):e89741.PubMedPubMedCentralGoogle Scholar
  58. 58.
    •• Stokholm MG, Iranzo A, Østergaard K, Serradell M, Otto M, Svendsen KB, et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol. 2017;16(10):789–96 This study investigated the potential role of the PK ligand as a clinical marker of short-term conversion to a synucleinopathy in patients with iRBD. PubMedGoogle Scholar
  59. 59.
    Iannaccone S, Cerami C, Alessio M, Garibotto V, Panzacchi A, Olivieri S, et al. In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(1):47–52.PubMedGoogle Scholar
  60. 60.
    Smith JA, Das A, Ray SK, Banik NL. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull. 2012;87(1):10–20.PubMedGoogle Scholar
  61. 61.
    Kobylecki C, Counsell SJ, Cabanel N, Wächter T, Turkheimer FE, Eggert K, et al. Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. Parkinsonism Relat Disord. 2013;19(5):527–32.PubMedGoogle Scholar
  62. 62.
    Gerhard A, Banati RB, Goerres GB, Cagnin A, Myers R, Gunn RN, et al. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology. 2003;61(5):686–9.PubMedGoogle Scholar
  63. 63.
    Schwarz SC, Seufferlein T, Liptay S, Schmid RM, Kasischke K, Foster OJ, et al. Microglial activation in multiple system atrophy: a potential role for NF-kappaB/rel proteins. Neuroreport. 1998;9(13):3029–32.PubMedGoogle Scholar
  64. 64.
    Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord. 2010;25(1):97–107.PubMedGoogle Scholar
  65. 65.
    Gerhard A, Watts J, Trender-Gerhard I, Turkheimer F, Banati RB, Bhatia K, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord. 2004;19(10):1221–6.PubMedGoogle Scholar
  66. 66.
    Henkel K, Karitzky J, Schmid M, Mader I, Glatting G, Unger JW, et al. Imaging of activated microglia with PET and [11C] PK 11195 in corticobasal degeneration. Mov Disord. 2004;19(7):817–21.PubMedGoogle Scholar
  67. 67.
    Turner MR, Cagnin A, Turkheimer FE, Miller CCJ, Shaw CE, Brooks DJ, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15(3):601–9.PubMedGoogle Scholar
  68. 68.
    Turner MR, Gerhard A, Al-Chalabi A, Shaw CE, Hughes RAC, Banati RB, et al. Mills’ and other isolated upper motor neurone syndromes: in vivo study with 11C-(R)-PK11195 PET. J Neurol Neurosurg Psychiatry. 2005;76(6):871–4.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One. 2012;7(12):e52941.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Zürcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. NeuroImage Clin. 2015;7:409–14.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol. 2001;60(2):161–72.PubMedGoogle Scholar
  72. 72.
    Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology. 2006;66(11):1638–43.PubMedGoogle Scholar
  73. 73.
    Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Microglial activation in presymptomatic Huntington’s disease gene carriers. Brain J Neurol. 2007;130(Pt 7):1759–66.Google Scholar
  74. 74.
    Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P. Hypothalamic involvement in Huntington’s disease: an in vivo PET study. Brain J Neurol. 2008;131(Pt 11):2860–9.Google Scholar
  75. 75.
    Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES. Disintegration of the sleep-wake cycle and circadian timing in Huntington’s disease. J Neurosci. 2005;25(1):157–63.PubMedGoogle Scholar
  76. 76.
    Politis M, Lahiri N, Niccolini F, Su P, Wu K, Giannetti P, et al. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington’s disease gene carriers. Neurobiol Dis. 2015;83:115–21.PubMedGoogle Scholar
  77. 77.
    Simmons DA, James ML, Belichenko NP, Semaan S, Condon C, Kuan J, et al. TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington’s disease: preclinical evidence with the p75NTR ligand LM11A-31. Hum Mol Genet. 2018;27(16):2893–912.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Turkheimer FE, Rizzo G, Bloomfield PS, Howes O, Zanotti-Fregonara P, Bertoldo A, et al. The methodology of TSPO imaging with positron emission tomography. Biochem Soc Trans. 2015;43(4):586–92.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Rizzo G, Veronese M, Tonietto M, Zanotti-Fregonara P, Turkheimer FE, Bertoldo A. Kinetic modeling without accounting for the vascular component impairs the quantification of [(11)C]PBR28 brain PET data. J Cereb Blood Flow Metab. 2014;34(6):1060–9.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Lavisse S, Guillermier M, Hérard A-S, Petit F, Delahaye M, Van Camp N, et al. Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci. 2012;32(32):10809–18.PubMedGoogle Scholar
  81. 81.
    • Janssen B, Vugts DJ, Funke U, Molenaar GT, Kruijer PS, van Berckel BNM, et al. Imaging of neuroinflammation in Alzheimer’s disease, multiple sclerosis and stroke: recent developments in positron emission tomography. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2016;1862(3):425–41 This review summarises the clinical and pre-clinical research using TSPO PET in these conditions, as well as discussing new molecular targets for imaging. Google Scholar
  82. 82.
    Ohnishi A, Senda M, Yamane T, Sasaki M, Mikami T, Nishio T, et al. Human whole-body biodistribution and dosimetry of a new PET tracer, [(11)C] ketoprofen methyl ester, for imagings of neuroinflammation. Nucl Med Biol. 2014;41(7):594–9.PubMedGoogle Scholar
  83. 83.
    Mu L, Slavik R, Müller A, Popaj K, Cermak S, Weber M, et al. Synthesis and preliminary evaluation of a 2-Oxoquinoline carboxylic acid derivative for PET imaging the cannabinoid type 2 receptor. Pharmaceuticals (Basel). 2014;7(3):339–52.Google Scholar
  84. 84.
    •• Tronel C, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Dupont A-C, Arlicot N. Molecular targets for PET imaging of activated microglia: the current situation and future expectations. Int J Mol Sci. 2017;18(4) The authors discuss the progress made in TSPO PET imaging, as well as the current limitations and pitfalls faced. They provide an overview of alternative molecular targets and how they may enhance our understanding of microglial activation in neurodegenerative conditions. PubMedCentralGoogle Scholar
  85. 85.
    •• Fan Z, Calsolaro V, Atkinson RA, Femminella GD, Waldman A, Buckley C, et al. Flutriciclamide (18F-GE180) PET: first-in-human PET study of novel third-generation in vivo marker of human translocator protein. J Nucl Med. 2016;57(11):1753–9 The first published study to demonstrate the kinetic properties of a third-generation TSPO radioligand. PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Laura Best
    • 1
  • Christine Ghadery
    • 2
    Email author
  • Nicola Pavese
    • 1
  • Yen Foung Tai
    • 3
  • Antonio P. Strafella
    • 2
  1. 1.Clinical Ageing Research UnitNewcastle University, Campus for Ageing and VitalityNewcastle Upon TyneUK
  2. 2.The Edmond J. Safra Program in Parkinson’s Disease & Movement Disorder Unit, Toronto Western Hospital & Krembil Research Institute, University Health Network; Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental HealthUniversity of TorontoTorontoCanada
  3. 3.Imperial College London, South Kensington CampusLondonUK

Personalised recommendations